Immix Biopharma Inc IMMX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Immix Biopharma Reports Third Quarter 2026 Financial Results and Update on Corporate Progress
Immix Biopharma’s NXC-201 NEXICART-2 Interim Clinical Trial Results Selected for Oral Presentation at ASH 2026
Immix Biopharma to Participate in the 45th Annual J.P. Morgan Healthcare Conference
Immix Biopharma Announces Closing of $125 Million Underwritten Offering of Common Stock
Immix Biopharma Announces Pricing of $125 Million Underwritten Offering of Common Stock
Immix Biopharma Announces 89% Complete Response Rate at Interim Update Across All NEXICART-2 Patients, with MRD-Negativity Indicating Potential to Reach up to 98% Complete Response Rate, Supporting Potential Best-in-Class Therapy for Relapsed/Refractory AL Amyloidosis
Trading Information
- Previous Close Price
- $7.20
- Day Range
- $7.06–7.43
- 52-Week Range
- $3.79–15.08
- Bid/Ask
- $7.15 / $7.19
- Shares Outstanding
- 83.81M
- Market Cap
- $599.26M
- Volume/Avg
- 356,875 / 1M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 21
- Website
- https://www.immixbio.com
Valuation
Metric | IMMX |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.80 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
IMMX
Financial Strength
Metric | IMMX |
|---|---|
Quick Ratio | 33.55 |
Current Ratio | 33.72 |
Interest Coverage | — |
Quick Ratio
IMMX
Profitability
Metric | IMMX |
|---|---|
Return on Assets (Normalized) | −27.13% |
Return on Equity (Normalized) | −29.13% |
Return on Invested Capital (Normalized) | −30.83% |
Return on Assets
IMMX
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|$w^<Nx | LOCK|dnTM& | $135B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|c%sVHs | LOCK|%f!?< | $99B | |||
| Moderna Inc MRNA | LOCK|&y@t#c& | LOCK|m<l | $84B | |||
| argenx SE ADR ARGX | LOCK|cx!KXS | LOCK|s^ | $59B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|@r!wCK | LOCK|<! | $48B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|<?T%S&?Z | LOCK|T&#Jc | $31B | |||
| Incyte Corp INCY | LOCK|^$?D$X | LOCK|%h# | $24B | |||
| BioNTech SE ADR BNTX | LOCK|>kCT$% | LOCK|X<! | $21B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|bbggWd | LOCK|^%&gn | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|XT?&h%K | LOCK|Rcz | $15B |